{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MGMT-Unmethylated+Glioblastoma&page=2", "query": { "condition": "MGMT-Unmethylated Glioblastoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MGMT-Unmethylated+Glioblastoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T02:16:02.245Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00813943", "title": "Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Cilengitide (2-times weekly)", "type": "DRUG" }, { "name": "cilengitide (5-times weekly)", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2009-03", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00813943" }, { "nct_id": "NCT06504381", "title": "DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Glioma", "MGMT-Unmethylated Glioblastoma", "MGMT-Methylated Glioblastoma" ], "interventions": [ { "name": "DB107-RRV", "type": "GENETIC" }, { "name": "DB107-FC", "type": "DRUG" }, { "name": "Radiation Therapy (RT)", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "Surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "GENETIC", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-01-08", "completion_date": "2042-01-31", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 5, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06504381" }, { "nct_id": "NCT03522298", "title": "Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma, Adult" ], "interventions": [ { "name": "Paxalisib (GDC-0084)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kazia Therapeutics Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-05-15", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03522298" }, { "nct_id": "NCT06388733", "title": "A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma", "GBM", "Brain Neoplasms, Adult, Malignant", "Brain Tumor" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ivy Brain Tumor Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2024-06-19", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Guilford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06388733" }, { "nct_id": "NCT03107780", "title": "Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "MGMT-Unmethylated Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Navtemadlin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2018-07-09", "completion_date": "2025-08-15", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Los Angeles, California • Baltimore, Maryland + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03107780" }, { "nct_id": "NCT06973096", "title": "CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "CART-EGFR-IL13Ra2 cells", "type": "DRUG" }, { "name": "Rituximab or Rituximab biosimilar", "type": "BIOLOGICAL" }, { "name": "Fludarabine + Cyclophosphamide combination", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2025-07-18", "completion_date": "2042-07", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973096" }, { "nct_id": "NCT06359379", "title": "Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma, IDH-wildtype" ], "interventions": [ { "name": "Ropidoxuridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shuttle Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-09-02", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06359379" }, { "nct_id": "NCT03452930", "title": "Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Gliosarcoma", "MGMT-Unmethylated Glioblastoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Tinostamustine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2018-08-13", "completion_date": "2024-06-05", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03452930" }, { "nct_id": "NCT05879250", "title": "WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma, IDH-Wildtype", "MGMT-Unmethylated Glioblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "STAT3 Inhibitor WP1066", "type": "DRUG" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2024-05-22", "completion_date": "2028-12-27", "has_results": false, "last_update_posted_date": "2025-12-30", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 2, "location_summary": "Chicago, Illinois • Warrenville, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05879250" }, { "nct_id": "NCT02617589", "title": "An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 560, "start_date": "2016-03-01", "completion_date": "2022-03-04", "has_results": true, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-05-22T02:16:02.245Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02617589" } ] }